ストックスクリーナーアプリを入手
131.06
0.82%
-0.90
アフターアワーズ：
130.75
-0.31
-0.24%
前日終値:
$131.96
開ける：
$131.87
24時間の取引高:
1.45M
Relative Volume:
1.20
時価総額：
$7.39B
収益：
$763.34M
当期純損益:
$51.40M
株価収益率:
144.28
EPS:
0.9084
ネットキャッシュフロー:
$104.46M
1週間 パフォーマンス:
-10.04%
1か月 パフォーマンス:
-10.97%
6か月 パフォーマンス:
-20.01%
1年 パフォーマンス:
+7.51%
1日の値動き範囲:
$130.03
$133.35
1週間の範囲:
$129.00
$148.37
52週間の値動き範囲:
$100.99
$175.77
Repligen Corp Stock (RGEN) Company Profile
Compare RGEN vs ISRG, BDX, MDLN, ALC, RMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RGEN
Repligen Corp
|
131.06 | 7.44B | 763.34M | 51.40M | 104.46M | 0.9084 |
ISRG
Intuitive Surgical Inc
|
356.83 | 120.92B | 11.03B | 3.16B | 3.22B | 8.7251 |
BDX
Becton Dickinson Co
|
158.92 | 43.08B | 21.37B | 1.41B | 3.07B | 3.9437 |
MDLN
Medline Inc
|
39.70 | 32.77B | 29.14B | 1.07B | 1.05B | 1.1956 |
ALC
Alcon Inc
|
67.28 | 33.12B | 10.63B | 819.00M | 1.59B | 1.6577 |
RMD
Resmed Inc
|
203.08 | 28.33B | 5.54B | 1.52B | 1.74B | 10.37 |
Repligen Corp Stock (RGEN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-17 | 開始されました | Rothschild & Co Redburn | Buy |
| 2025-10-01 | 開始されました | HSBC Securities | Buy |
| 2025-09-22 | アップグレード | Evercore ISI | In-line → Outperform |
| 2025-07-22 | 再開されました | Stephens | Overweight |
| 2025-06-24 | 開始されました | Barclays | Overweight |
| 2025-04-29 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2025-03-18 | 開始されました | Evercore ISI | In-line |
| 2025-02-10 | 開始されました | TD Cowen | Buy |
| 2024-12-17 | 開始されました | Canaccord Genuity | Hold |
| 2024-11-14 | 開始されました | Wolfe Research | Peer Perform |
| 2024-08-28 | 開始されました | Wells Fargo | Overweight |
| 2024-06-26 | アップグレード | Deutsche Bank | Hold → Buy |
| 2024-06-18 | 開始されました | Guggenheim | Neutral |
| 2023-12-04 | ダウングレード | The Benchmark Company | Buy → Hold |
| 2023-07-20 | 開始されました | Wells Fargo | Overweight |
| 2023-07-05 | 再開されました | JP Morgan | Overweight |
| 2023-03-28 | 開始されました | The Benchmark Company | Buy |
| 2022-12-14 | 開始されました | Deutsche Bank | Hold |
| 2022-12-07 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2022-07-20 | 開始されました | UBS | Buy |
| 2021-10-14 | 開始されました | Exane BNP Paribas | Outperform |
| 2020-11-10 | 開始されました | KeyBanc Capital Markets | Overweight |
| 2020-08-24 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-06-30 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-05-07 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-03-23 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-11-15 | 開始されました | Stifel | Buy |
| 2019-11-01 | アップグレード | First Analysis Sec | Outperform → Strong Buy |
| 2019-10-15 | 開始されました | SVB Leerink | Outperform |
| 2019-08-28 | 繰り返されました | First Analysis Sec | Outperform |
| 2019-08-23 | 再開されました | Stephens | Overweight |
| 2019-07-22 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2018-12-17 | アップグレード | CL King | Neutral → Buy |
| 2018-11-12 | ダウングレード | CL King | Buy → Neutral |
| 2018-09-26 | 開始されました | H.C. Wainwright | Neutral |
| 2017-12-08 | 開始されました | Citigroup | Buy |
| 2017-12-05 | 開始されました | JP Morgan | Overweight |
| 2017-11-13 | 開始されました | CL King | Buy |
| 2017-10-02 | アップグレード | First Analysis Sec | Equal-Weight → Overweight |
| 2017-07-21 | 開始されました | William Blair | Outperform |
| 2017-02-13 | アップグレード | Piper Jaffray | Neutral → Overweight |
すべてを表示
Repligen Corp (RGEN) 最新ニュース
Repligen (RGEN) Q2 Earnings: What To Expect - Yahoo! Finance Canada
ETFs Investing in Repligen Corporation Stocks - TradingView
Repligen Corp (RGEN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Repligen Corp (RGEN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Repligen Corporation (RGEN) stock price, news, quote and history - Yahoo Finance UK
Repligen Corp (RGEN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Repligen Corp|Price:131.970|Chg%:-5.630 - TradingKey
RGEN|Repligen Corp|Price:130.951|Chg%:-1.009 - TradingKey
Repligen’s $1.5 Billion Acquisition Could Reshape Its Growth Story! - Smartkarma
Repligen Corporation (RGEN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Daily Brief Health Care: Shanghai Shengsheng Pharmaceutical Cold Chain Technology, Akeso, Mitesco Inc, Nagaileben, Repligen Corp, Scribe Therapeutics, Cosmos Health and more - Smartkarma
Is Repligen Corp (RGEN) a Bargain After 4.1% Drop? GF Value Says Undervalued - GuruFocus
Repligen Corp (RGEN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Repligen Corporation to Acquire BioLife Solutions for $1.5 Billion, Boosting Cell Therapy Market Presence - Kalkine Media
Repligen to buy BioLife Solutions (NASDAQ: BLFS) in $1.5B cash-and-stock deal - Stock Titan
Repligen Corp (RGEN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Repligen to Expand Cell Therapy Capabilities With BioLife Buyout - Zacks Investment Research
RGEN stock holds steady as Repligen backs 2026 growth - Ad-hoc-news.de
Canaccord reiterates Hold on Repligen stock after BioLife deal By Investing.com - Investing.com Nigeria
Canaccord reiterates Hold on Repligen stock after BioLife deal - Investing.com
Bothell firm fetches $1.5 billion in acquisition by Massachusetts company - The Business Journals
Repligen to Acquire BioLife Solutions for $1.5 Billion, Expanding Leadership in Cell Therapy Market - Minichart
Repligen to Acquire Bothell's BioLife Solutions in $1.5B Deal - 425business.com
Repligen to buy BioLife Solutions (NASDAQ: BLFS) in $1.5B cash-stock deal - Stock Titan
Repligen to Acquire BioLife Solutions for $11.25 per Share Plus Stock, Enhancing Cell Processing Capabilities - Kalkine Media
US759916AC3 Bond Profile — Key Metrics - TradingView
Repligen to Buy BioLife Solutions for $1.5 Billion, Expanding Cell Therapy Reach - Yahoo Finance
Repligen to buy BioLife in $1.5 billion deal to expand cell therapy business - ETPharma.com
Repligen targets cell therapy expansion as Waltham firm inks $1.5 billion acquisition - The Business Journals
Repligen to Acquire BioLife Solutions in $1.5 Billion Cash-and-Stock Deal, Expanding Into Cell Therapy - finance.biggo.com
Repligen beefs up cell therapy business with $1.5 billion deal for BioLife - Reuters
Repligen Announces Acquisition of BioLife Solutions in $11.25 Per Share Cash and Stock Deal - Kalkine Media
Repligen to Acquire BioLife Solutions in Cash and Stock Merger Valued at $11.25 Per Share - Kalkine Media
What's Going on With Repligen Stock Wednesday?Repligen (NASDAQ:RGEN), BioLife Solutions (NASDAQ:BLFS) - Benzinga
Repligen Corporation (Nasdaq: RGEN) sets cash–stock deal to buy BioLife - Stock Titan
Repligen to Acquire BioLife Solutions in Cash-and-Stock Deal; $11.25 Plus 0.1442 Shares Per Share - TradingView
Repligen Corp: If Deal Terminated Under Some - Moomoo
Repligen to Acquire BioLife Solutions in $1.5 Billion Deal - sekbernews.id
Repligen Corp To Acquire BioLife Solutions Transcript - GuruFocus
Repligen to buy cell therapy maker BioLife in $1.5 billion deal - MSN
Repligen to acquire BioLife Solutions for $1.5 billion - Investing.com
BioLife’s Biopreservation Media Supports 18 Commercially Approved Therapies - Stock Titan
A Look at Repligen Corp (RGEN) After 5.9% Decline -- GF Value $1 - GuruFocus
Why Repligen (RGEN) Stock Is Trading Lower Today - Yahoo Finance
Repligen Corporation (RGEN) Stock Forecasts - Yahoo Finance
Repligen to buy BioLife Solutions (NASDAQ: BLFS) in cash and stock merger - Stock Titan
Form 4 Repligen Corporation For: 17 July By Investing.com - Investing.com South Africa
Repligen CFO Jason K Garland sells $79,500 in stock - Investing.com UK
Repligen CFO Jason K Garland sells $79,500 in stock By Investing.com - Investing.com Nigeria
Repligen CFO Jason Garland Sells 530 Shares Under Pre-Arranged Rule 10b5-1 Trading Plan - Kalkine Media
Insider Sell: Jason Garland Sells Shares of Repligen Corp (RGEN) - GuruFocus
Repligen Corp (RGEN) 財務データ
収益
当期純利益
現金流量
EPS
0.62%
0.01%
大文字化:
|
ボリューム (24 時間):